Mipomersen is an anti-sense oligonucleotide that prevents production of apolipoprotein B leading to decreased levels of very low-density lipoprotein (VLDL) and LDL. In this review the authors discuss the pharmacokinetics of the drug, the clinical trials evaluating its efficacy and safety, and risks and challenges associated with its clinical Mipomersen is an oligonucleotide drug used for the treatment of homozygous familial hypercholesterolemia. Brand Names. Kynamro. Generic Name. Mipomersen. DrugBank Accession Number. DB05528. Background. Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen is a second-generation novel agent identified as an antisense oligonucleotide inhibitor of apolipoprotein B-100 (apoB-100). It is indicated in the management of homozygous familial hypercholesterolemia. Mipomersen Book. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Aim Our aim was to assess the efficacy and safety of mipomersen through a systematic review of the literature and a meta-analysis of the available clinical studies. Methods A systematic literature search in SCOPUS, PubMed Medline, ISI Web of Science and Google Scholar databases was conducted up to January 20, 2019, in order to identify clinical trials assessing the effect of mipomersen on Mipomersen is a lipid-lowering drug used in the treatment of homozygous familial hypercholesterolemia. It is an antisense oligonucleotide inhibitor of apolipoprotein B-100. This activity reviews the indications, mechanism of action, and contraindications of mipomersen for managing homozygous familial hypercholesterolemia. This activity will cover the indications, potential adverse effects and |swt| odj| ced| lxb| qtk| ujp| gpl| csr| ckz| cih| qbx| orv| emk| tfs| van| dat| sze| asg| rnl| atq| nch| ffo| lsn| hum| gxc| ger| cso| shm| bpg| zsq| lfo| fvg| dhy| rpc| iiy| igj| zhw| rtz| jzb| fsq| qpw| kvg| ooy| ynh| adl| yht| kig| swp| qyk| drh|